NorthStar Medical Radioisotopes, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx, a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, entered a collaboration to develop and produce novel radiopharmaceuticals for the treatment of cancer. Inhibrx will use its optimized single-domain antibodies (sdAbs) to create a new generation o...